IGC Pharma annual operating expenses
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2025
IGC Pharma Operating Expenses Growth & History (IGC)
IGC Pharma's operating expenses was $8.0M for fiscal 2025.
View full IGC Pharma company overviewIGC Pharma annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 · Dec 31 | 2025-12-31 | $8.0M | — | — |
| 2025 · Mar 31 | 2025-03-31 | $8.1M | −$2.5M | −23.42% |
| 2024 | 2024-03-31 | $10.5M | −$1.5M | −12.34% |
| 2023 | 2023-03-31 | $12.0M | −$3.6M | −23.10% |
| 2022 | 2022-03-31 | $15.6M | $6.8M | +76.78% |
| 2021 | 2021-03-31 | $8.8M | $1.9M | +26.62% |
| 2020 | 2020-03-31 | $7.0M | $2.2M | +46.16% |
| 2019 | 2019-03-31 | $4.8M | $2.9M | +155.21% |
| 2018 | 2018-03-31 | $1.9M | −$401,622 | −17.67% |
| 2017 | 2017-03-31 | $2.3M | −$1.5M | −39.38% |
| 2016 | 2016-03-31 | $3.7M | −$1.2M | −23.83% |
| 2015 | 2015-03-31 | $4.9M | $2.0M | +69.18% |
| 2014 | 2014-03-31 | $2.9M | −$1.1M | −27.57% |
| 2013 | 2013-03-31 | $4.0M | −$2.9M | −41.73% |
| 2012 | 2012-03-31 | $6.9M | −$9.2M | −57.04% |
| 2011 | 2011-03-31 | $16.0M | — | — |
IGC Pharma quarterly operating expenses
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 · Jun 30 | 2026-06-30 | $2.8M | $773,000 | +37.54% |
| Q1 2026 · Mar 31 | 2026-03-31 | $2.5M | $946,000 | +60.37% |
| Q4 2025 | 2025-12-31 | $1.4M | −$564,000 | −28.46% |
| Q2 2026 · Sep 30 | 2025-09-30 | $3.0M | $1.0M | +53.12% |
| Q1 2026 · Jun 30 | 2025-06-30 | $2.1M | −$500,000 | −19.54% |
| Q4 2025 | 2025-03-31 | $1.6M | −$774,000 | −33.06% |
| Q3 2025 | 2024-12-31 | $2.0M | −$1.1M | −36.70% |
| Q2 2025 | 2024-09-30 | $2.0M | −$707,000 | −26.53% |
| Q1 2025 | 2024-06-30 | $2.6M | $165,000 | +6.89% |
| Q4 2024 | 2024-03-31 | $2.3M | −$1.7M | −42.42% |
| Q3 2024 | 2023-12-31 | $3.1M | $751,000 | +31.55% |
| Q2 2024 | 2023-09-30 | $2.7M | $42,000 | +1.60% |
| Q1 2024 | 2023-06-30 | $2.4M | −$550,000 | −18.68% |
| Q4 2023 | 2023-03-31 | $4.1M | −$2.5M | −38.10% |
| Q3 2023 | 2022-12-31 | $2.4M | −$67,000 | −2.74% |
| Q2 2023 | 2022-09-30 | $2.6M | −$1.8M | −40.20% |
| Q1 2023 | 2022-06-30 | $2.9M | $724,000 | +32.61% |
| Q4 2022 | 2022-03-31 | $6.6M | $3.8M | +133.11% |
| Q3 2022 | 2021-12-31 | $2.4M | $107,000 | +4.57% |
| Q2 2022 | 2021-09-30 | $4.4M | $2.7M | +157.70% |
| Q1 2022 | 2021-06-30 | $2.2M | $243,000 | +12.29% |
| Q4 2021 | 2021-03-31 | $2.8M | $359,000 | +14.60% |
| Q3 2021 | 2020-12-31 | $2.3M | $632,000 | +37.00% |
| Q2 2021 | 2020-09-30 | $1.7M | $386,000 | +29.33% |
| Q1 2021 | 2020-06-30 | $2.0M | $481,000 | +32.15% |
| Q4 2020 | 2020-03-31 | $2.5M | $733,000 | +42.47% |
| Q3 2020 | 2019-12-31 | $1.7M | $85,000 | +5.24% |
| Q2 2020 | 2019-09-30 | $1.3M | $443,000 | +50.74% |
| Q1 2020 | 2019-06-30 | $1.5M | $943,000 | +170.52% |
| Q4 2019 | 2019-03-31 | $1.7M | $1.1M | +196.72% |
| Q3 2019 | 2018-12-31 | $1.6M | $1.1M | +216.99% |
| Q2 2019 | 2018-09-30 | $873,000 | $538,000 | +160.60% |
| Q1 2019 | 2018-06-30 | $553,000 | $110,685 | +25.02% |
| Q4 2018 | 2018-03-31 | $581,685 | −$150,147 | −20.52% |
| Q3 2018 | 2017-12-31 | $512,000 | −$2,084 | −0.41% |
| Q2 2018 | 2017-09-30 | $335,000 | −$286,262 | −46.08% |
| Q1 2018 | 2017-06-30 | $442,315 | $36,871 | +9.09% |
| Q4 2017 | 2017-03-31 | $731,832 | −$1.3M | −63.99% |
| Q3 2017 | 2016-12-31 | $514,084 | −$66,916 | −11.52% |
| Q2 2017 | 2016-09-30 | $621,262 | −$52,946 | −7.85% |
| Q1 2017 | 2016-06-30 | $405,444 | −$55,933 | −12.12% |
| Q4 2016 | 2016-03-31 | $2.0M | −$18,128 | −0.88% |
| Q3 2016 | 2015-12-31 | $581,000 | −$117,276 | −16.80% |
| Q2 2016 | 2015-09-30 | $674,208 | −$272,374 | −28.77% |
| Q1 2016 | 2015-06-30 | $461,377 | −$765,198 | −62.38% |
| Q4 2015 | 2015-03-31 | $2.1M | $516,225 | +33.65% |
| Q3 2015 | 2014-12-31 | $698,276 | $394,520 | +129.88% |
| Q2 2015 | 2014-09-30 | $946,582 | $323,781 | +51.99% |
| Q1 2015 | 2014-06-30 | $1.2M | $778,156 | +173.53% |
| Q4 2014 | 2014-03-31 | $1.5M | −$1.1M | −41.37% |
| Q3 2014 | 2013-12-31 | $303,756 | $15,182 | +5.26% |
| Q2 2014 | 2013-09-30 | $622,801 | $35,893 | +6.12% |
| Q1 2014 | 2013-06-30 | $448,419 | −$75,950 | −14.48% |
| Q4 2013 | 2013-03-31 | $2.6M | −$1.8M | −40.11% |
| Q3 2013 | 2012-12-31 | $288,574 | −$722,676 | −71.46% |
| Q2 2013 | 2012-09-30 | $586,908 | −$141,088 | −19.38% |
| Q1 2013 | 2012-06-30 | $524,369 | −$260,016 | −33.15% |
| Q4 2012 | 2012-03-31 | $4.4M | −$8.6M | −66.35% |
| Q3 2012 | 2011-12-31 | $1.0M | −$505,271 | −33.32% |
| Q2 2012 | 2011-09-30 | $727,996 | −$136,647 | −15.80% |
| Q1 2012 | 2011-06-30 | $784,385 | $107,045 | +15.80% |
| Q4 2011 | 2011-03-31 | $13.0M | — | — |
| Q3 2011 | 2010-12-31 | $1.5M | — | — |
| Q2 2011 | 2010-09-30 | $864,643 | — | — |
| Q1 2011 | 2010-06-30 | $677,340 | — | — |
IGC Pharma operating expenses trends
Between the periods ended 2011-03-31 and 2025-12-31, IGC Pharma's operating expenses decreased from $16.0M to $8.0M, a change of −$8.0M. The latest reported quarter, Q2 2026 · Jun 30, shows $2.8M.
About the metric
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
Calculation and source
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review IGC Pharma source filings ↗